Skip to content
MARKETS / BALCAO / ABPO
BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Abpro Holdings, Inc. ABPO

4 fiscal years on record · USD · FY2025 reported · SEC filings only
$-2.9M
In brief

What this company does

DiversImmune® is our antibody discovery platform that rapidly generates a diverse collection of proprietary antibodies against both clinically validated and novel targets that have been traditionally difficult to access. This provides us with high affinity and high specificity antibody building blocks with drug-like properties that we then use to engineer novel therapeutics. MultiMab™ is our engineering platform that provides us with the flexibility to combine these antibody building blocks in different combinations and orientations to rapidly create “fit for purpose” novel full-length multi-specific antibody constructs. Our antibody constructs, including our TetraBi antibody format, can potentially benefit patients with the goal of improved efficacy, better safety profiles, and more convenient dosing regimens relative to current standard-of-care therapies.

Written from the business description in Abpro Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 15 April 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 4-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.2 · Net income -7.2
-4M-8M2022202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2024 · Operating -5421.3% · Net -3951.9%
-5000%2022202320242025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Net buybacks $M Dividends $M
FY2023 · Dividends — · Net buybacks 276.5
100M200M20222023

Total assetsUSD 1.1M
EquityUSD -8.8M
CashUSD 82,000.00
Current ratio0.10×

Equity funds -831% of total assets.

The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022
Revenue $B·0.00.0·
Operating income $B−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0·
Income tax $B··0.00.0
Net income $B−0.0−0.0−0.00.0
Free cash flow $B··−0.0·
EPS, diluted $−1.30−22.31−0.61·
Dividend / sh $····
Payout %····
ROE %····
Shares out B0.000.000.02·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures in 15 reconciliationsAUDITED

Reconciled in 3 of 19 fiscal years. 61 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2022

Share this section

Download image